These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 16123716)

  • 1. Cytomegalovirus-related complications in human hand transplantation.
    Schneeberger S; Lucchina S; Lanzetta M; Brandacher G; Bösmüller C; Steurer W; Baldanti F; Dezza C; Margreiter R; Bonatti H
    Transplantation; 2005 Aug; 80(4):441-7. PubMed ID: 16123716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention].
    Antretter H; Höfer D; Klaus A; Larcher C; Margreiter J; Margreiter R
    Dtsch Med Wochenschr; 2000 Apr; 125(15):445-51. PubMed ID: 10800441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.
    Slifkin M; Ruthazer R; Freeman R; Bloom J; Fitzmaurice S; Fairchild R; Angelis M; Cooper J; Barefoot L; Rohrer R; Snydman DR
    Liver Transpl; 2005 Dec; 11(12):1597-602. PubMed ID: 16315314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
    Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
    Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
    Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment.
    Loginov R; Höckerstedt K; Lautenschlager I
    Arch Virol; 2003 Jul; 148(7):1269-74. PubMed ID: 12827460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infectious complications in three double hand recipients: experience from a single center.
    Bonatti H; Brandacher G; Margreiter R; Schneeberger S
    Transplant Proc; 2009 Mar; 41(2):517-20. PubMed ID: 19328916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
    Perrella A; Esposito C; Ioia G; Campanella L; Taglialatela D; Cuomo O
    Transplant Proc; 2010 May; 42(4):1226-8. PubMed ID: 20534267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients.
    Said T; Nampoory MR; Pacsa AS; Essa S; Madi N; Fahim N; Abraham M; Nair P; Al-Otaibi T; Halim MA; Johny KV; Al-Mousawi M
    Transplant Proc; 2007 May; 39(4):997-9. PubMed ID: 17524873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.
    Andrei G; Van Loon E; Lerut E; Victoor J; Meijers B; Bammens B; Sprangers B; Gillemot S; Fiten P; Opdenakker G; Lagrou K; Kuypers D; Snoeck R; Naesens M
    Antiviral Res; 2019 Aug; 168():203-209. PubMed ID: 31212020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.